Atyr PHARMA INC (NASDAQ:ATYR) Receives $18.60 Average Target Price from Analysts

Atyr PHARMA INC (NASDAQ:ATYR) has been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $18.60.

Several equities analysts have issued reports on ATYR shares. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Leerink Partners initiated coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th.

Atyr PHARMA Stock Up 8.4 %

Shares of NASDAQ:ATYR opened at $2.97 on Wednesday. The company’s fifty day moving average is $3.46 and its 200-day moving average is $3.26. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a market capitalization of $263.91 million, a PE ratio of -3.16 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Equities research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atyr PHARMA

Institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $144,000. Victory Capital Management Inc. acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth $37,000. D.A. Davidson & CO. bought a new stake in Atyr PHARMA in the fourth quarter valued at about $141,000. Knott David M Jr bought a new position in Atyr PHARMA during the fourth quarter worth about $1,115,000. Finally, JPMorgan Chase & Co. boosted its holdings in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after buying an additional 10,754 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.